Business
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2025 Cell & Gene Meeting on the Mesa Conference taking place October 6-8 in Phoenix, Arizona. “T
About this update from Fibrobiologics, Inc.
[{"type":"image","alt":"FibroBiologics, Inc.","displaySize":"","headline":null,"caption":"FibroBiologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xw_QEbMhw7ViThavcOHCOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425","width":300,"height":77}},"lazy":false},{"type":"text","content":"HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2025 Cell & Gene Meeting on the Mesa Conference taking place October 6-8 in Phoenix, Arizona.","length":501,"tagName":"p"},{"type":"text","content":"“The Cell & Gene Meeting on the Mesa provides an excellent opportunity to share updates on our fibroblast-based technologies and their potential to address unmet needs in several indications,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “We look forward to providing continued updates as we advance our pipeline, including the initiation of our clinical trial for diabetic foot ulcers planned for the first quarter of 2026.”","length":453,"tagName":"p"},{"type":"text","content":"Details of the presentations are as follows:","length":44,"tagName":"p"},{"type":"text","content":"Event: 2025 Cell & Gene Meeting on the MesaSession Date and Time: October 7, 2025, at 2:15 p.m. MSTLocation: FLW Ballroom F","length":144,"tagName":"p"},{"type":"text","content":"For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected].","length":130,"tagName":"p"},{"type":"text","content":"Cautionary Statement Regarding Forward-Looking StatementsThis communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of ...